Advertisement

Pharmaceutisch Weekblad

, Volume 14, Issue 4, pp 206–220 | Cite as

Dealing with sadness, madness and hostility

New psychotropic drug remedies for the future
  • Anton J. M. Loonen
Drugs in the Pipeline

Abstract

The objective of this article is to present an overview of new forms of psychotropic drug therapy that may be expected to play a role in psychiatric practice in the 1990s. In predicting these future developments, three lines of approach have been followed. Firstly, progress in elucidating basic neuronal mechanisms is described. The radioligand receptor binding technique has proved to be an especially powerful tool in the search for novel psychoactive compounds. Secondly, those mental health problems most likely to undergo intensive study are discussed. It is likely that special attention will be devoted to organic mental disorders related to aging (dementia) or chronic exposure to toxic substances. In addition, research will be aimed at explaining and reducing the occurrence of auto-aggressive and hetero-aggressive behaviour. Thirdly, the types of newly designed agents and treatment strategies currently under investigation are outlined. In particular, the development of pharmacological agents that interfere with serotonergic molecular mechanisms has opened the way to improving existing psychotropic drugs, to inventing drugs that achieve known clinical effects via different mechanisms of action, and even to discovering entirely new categories of psychotropic drugs.

Keywords

Antidepressive agents Drug design Mental disorders Neurosciences Psychotropic drugs Serenics Tranquilizing agents 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's The pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990:383–435.Google Scholar
  2. 2.
    Davis JM. Antipsychotic drugs. In: Kaplan HI, Freedman AM, Sadock BJ, eds. Comprehensive textbook of Pychiatry/III. 3rd ed. Baltimore: Williams & Wilkins, 1980:2257–89.Google Scholar
  3. 3.
    Terenius L. Characteristics of the ‘receptor’ for narcotic analgesics in synaptic plasma membrane fraction from rat brain. Acta Pharmacol Toxicol 1973;33: 377–84.Google Scholar
  4. 4.
    Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science 1973;179:1011–4.PubMedGoogle Scholar
  5. 5.
    Pert CB, Snyder SH. Properties of opiate-receptor binding in rat brain. Proc Natl Acad Sci USA 1973;70: 2243–7.PubMedGoogle Scholar
  6. 6.
    Simon EJ, Hiller JM, Edelman I. Stereospecific binding of the potent narcotic analgesic (3H)etorphine to rat-brain homogenate. Proc Natl Acad Sci USA 1973; 70:1947–9.PubMedGoogle Scholar
  7. 7.
    Watson S, Abbott A. TiPS receptor nomenclature supplement 1991. TiPS 1991;12 Suppl:1–36.Google Scholar
  8. 8.
    Langer SZ, Arbilla S, Tan S, Lloyd KG, George P, Allen J, Wick AE. Selectivity for omega-receptor subtypes as a strategy for the development of anxiolytic drugs. Pharmacopsychiatry 1990;23 Suppl 3:103–7.PubMedGoogle Scholar
  9. 9.
    Langer SZ, Arbilla S. Imidazopyridines as a tool for the characterization of benzodiazepine receptors: a proposal for a pharmacological classification as omega receptor subtypes. Pharmacol Biochem Behav 1988;29: 763–6.PubMedGoogle Scholar
  10. 10.
    Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990;347:146–51.PubMedGoogle Scholar
  11. 11.
    Van Tol HH, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350:610–4.PubMedGoogle Scholar
  12. 12.
    Sunahara RK, Guan HC, O'Dowd BF, et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 1991;350:614–9.PubMedGoogle Scholar
  13. 13.
    Tota MR, Candelore MR, Dixon RAF, Strader CD. Biophysical and genetic analysis of the ligand-binding site of theβ-adrenoceptor. TiPS 1991;12:4–6.PubMedGoogle Scholar
  14. 14.
    Hartig P, Kao HT, Macchi M, et al. The molecular biology of serotonin receptors. An overview. Neuropsychopharmacology 1990;3:335–47.PubMedGoogle Scholar
  15. 15.
    Gantz I, Schaffer M, DelValle J, et al. Molecular cloning of a gene encoding the histamine H2 receptor. Proc Natl Acad Sci USA 1991;88:429–33.PubMedGoogle Scholar
  16. 16.
    Olsen RW, Tobin AJ. Molecular biology of GABA-A receptors. FASEB J 1990;4:1469–80.PubMedGoogle Scholar
  17. 17.
    Bonner TI. The molecular basis of muscarinic receptor diversity. Trends Neurosci 1989;12:148–51.PubMedGoogle Scholar
  18. 18.
    Deneris ES, Connolly J, Rogers SW, Duvoisin R. Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors. TiPS 1991;12:34–40.PubMedGoogle Scholar
  19. 19.
    Haefely WE. Pharmacology of the benzodiazepine receptor. Eur Arch Psychiatry Neurol Sci 1989;238: 294–301.PubMedGoogle Scholar
  20. 20.
    Haefely W, Martin JR, Schoch P. Novel anxiolytics that act as partial agonists at benzodiazepine receptors. TiPS 1990;11:452–6.PubMedGoogle Scholar
  21. 21.
    Cox BM, Opheim KE, Teschemacher H, Goldstein A. A peptide-like substance from pituitary that acts like morphine. 2. Purification and properties. Life Sci 1975;16:1777–82.PubMedGoogle Scholar
  22. 22.
    Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 1975;258:577–80.PubMedGoogle Scholar
  23. 23.
    Hughes J. Isolation of an endogenous compound from the brain with pharmacological properties similar to morphine. Brain Res 1975;88:295–308.PubMedGoogle Scholar
  24. 24.
    Ling N, Burgus R, Guillemin R. Isolation, primary structure, and synthesis of alpha-endorphin and gamma-endorphin, two peptides of hypothalamichypophysial origin with morphinomimetic activity. Proc Natl Acad Sci, USA 1976;73:3042–6.Google Scholar
  25. 25.
    Terenius L, Wahlstrom A. Search for an endogenous ligand for the opiate receptor. Acta Physiol Scand 1975;94:74–81.PubMedGoogle Scholar
  26. 26.
    Teschemacher H, Opheim KE, Cox BM, Goldstein A. A peptide-like substance from pituitary that acts like morphine. I. Isolation. Life Sci 1975:16;1771–5.PubMedGoogle Scholar
  27. 27.
    Zetler G. Active peptides in the nervous tissue: historical prospects. Adv Biochem Psychopharmacol 1978;18:1–21.PubMedGoogle Scholar
  28. 28.
    Loonen AJM, Soudijn W. Peptides with a dual function: central neuroregulators and gut hormones. J Physiol 1979;75:831–50.Google Scholar
  29. 29.
    Loonen AJM. Neurocommunication and psychotropic drugs. Pharm Int 1982;3:59–64.Google Scholar
  30. 30.
    Rouissi N, Gitter BD, Waters DC, Howbert JJ, Nixon JA, Regoli D. Selectivity and specificity of new, nonpeptide, quinuclidine antagonists of substance P. Biochem Biophys Res Commun 1991;176:894–901.PubMedGoogle Scholar
  31. 31.
    Crawley JN. Cholecystokinin-dopamine interactions. TiPS 1991;12:232–6.PubMedGoogle Scholar
  32. 32.
    Cavagnaro J, Waterhouse GA, Lewis RM. Neuroendocrine-immune interactions: immunoregulatory signals mediated by neurohumoral agents. Year Immunol 1988;3:228–46.PubMedGoogle Scholar
  33. 33.
    Vollhardt LT. Psychoneuroimmunology: a literature review. Am J Orthopsychiatry 1991;61:35–47.PubMedGoogle Scholar
  34. 34.
    O'Leary A. Stress, emotion, and human immune function. Psychol Bull 1990;108:363–82.PubMedGoogle Scholar
  35. 35.
    Martin JB. Molecular genetic studies in the neuropsychiatric disorders. Trends Neurosci 1989;12:130–7.PubMedGoogle Scholar
  36. 36.
    Diekstra RFW. Suicide and the attempted suicide: an international perspective. Acta Psychiatr Scand 1989;80 Suppl 354:1–24.PubMedGoogle Scholar
  37. 37.
    Tamminga CA, Gerlach J. New neuroleptics and experimental antipsychotics in schizophrenia. In: Meltzer HY, ed. Psychopharmacology. The third generation of progress. New York: Raven Press, 1987:1129–40.Google Scholar
  38. 38.
    Wadworth AN, Heel RC. Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutical potential in schizophrenia. Drugs 1990;40:863–79.PubMedGoogle Scholar
  39. 39.
    Hall H, Ögren SO, Kohler C, Magnusson O. Animal pharmacology of raclopride, a selective dopamine D2 antagonist. Psychopharmacol Ser 1989;7:123–30.PubMedGoogle Scholar
  40. 40.
    Deutch AY, Moghaddam B, Innis RB, et al. Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia. Schizophren Res 1991;4:121–56.Google Scholar
  41. 41.
    Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989;50:329–38.PubMedGoogle Scholar
  42. 42.
    Fitton A, Heel RC. Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 1990;40:722–47.PubMedGoogle Scholar
  43. 43.
    Chipkin RE. D1 antagonist in clinical trial. TiPS 1990;11:185.Google Scholar
  44. 44.
    Hietala J, Lappalainen J, Koulu M, Syvalahti E. Dopamine D1 receptor antagonism in schizophrenia: is there reduced risk of extrapyramidal side-effects? TiPS 1990;11:406–10.PubMedGoogle Scholar
  45. 45.
    Anonymous. Pharmaprojects. New drugs in development. AN 016427 9101. Richmond: PJB Publications, 1991.Google Scholar
  46. 46.
    VandenBussche G, Gelders YG, Heylen SL. El desarrollo de nuevas drogas antipsicoticas. Acta Psiquiatr Psicol Am Lat 1990;36:13–25.PubMedGoogle Scholar
  47. 47.
    Reyntjens A, Gelders YG, Hoppenbrouwers MLJA, VandenBussche G. Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin-S2 receptor blocker. Drug Devel Res 1986;8:205–11.Google Scholar
  48. 48.
    Leysen JE, Gommeren W, Eens A, DeChaffoy-DeCourcelles D, Stoof JC, Jansen PA. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;247:661–70.PubMedGoogle Scholar
  49. 49.
    Hirose A, Kato T, Ohno Y et al. Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions. Jpn J Pharmacol 1990;53:321–9.PubMedGoogle Scholar
  50. 50.
    Ögren SO, Florvall L, Hall H, Magnusson O, Angeby-Moller K. Neuropharmacological and behavioural properties of remoxipride in the rat. Acta Psychiatr Scand 1990;82 Suppl 358:21–6.Google Scholar
  51. 51.
    Abbott A. 5-HT3 antagonists and ligands for dopamine D1- and autoreceptors offer new leads for antipsychotic drugs. TiPS 1990;11:49–51.PubMedGoogle Scholar
  52. 52.
    Heel RC, Morley PA, Brogden RN, Carmine AA, Speight TM, Avery GS. Zimelidine. A review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 1982;24:169–206.PubMedGoogle Scholar
  53. 53.
    Anonymous. CSM update. Adverse reactions to antidepressants. BMJ 1985;291:1638.Google Scholar
  54. 54.
    Fagius J, Osterman PO, Sidén A, Wiholm B-E. Guillain-Barré syndrome following zimeldine treatment. J Neurol Neurosurg Psychiatry 1985;48:65–9.PubMedGoogle Scholar
  55. 55.
    Benfield P, Ward A. Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986;32:313–34.PubMedGoogle Scholar
  56. 56.
    Benfield P, Heel RC, Lewis SP. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986;32:481–508.PubMedGoogle Scholar
  57. 57.
    Milne RJ, Goa KL. Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and potential in depressive illness. Drugs 1991;41:450–77.PubMedGoogle Scholar
  58. 58.
    Doogan DP, Caillard V. Sertraline: a new antidepressant. J Clin Psychiatry 1988;49 Suppl:46–51.Google Scholar
  59. 59.
    Koe BK. Preclinical pharmacology of sertraline: a potent and specific inhibitor of serotonin reuptake. J Clin Psychiatry 1990;51 Suppl B:13–7.Google Scholar
  60. 60.
    Dechant KL, Clissold SP. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991;41:225–53.PubMedGoogle Scholar
  61. 61.
    De Boer TH, Maura G, Raiteri M, De Vos CJ, Wieringa J, Pinder RM. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology 1988;27:399–408.PubMedGoogle Scholar
  62. 62.
    Smith WT, Glaudin V, Panagides J, Gilvary E. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990;26:191–6.PubMedGoogle Scholar
  63. 63.
    James WA, Lippmann S. Bupropion: overview and prescribing guidelines in depression. South Med J 1991;84:222–4.PubMedGoogle Scholar
  64. 64.
    Blackwell B. Newer antidepressant drugs. In: Meltzer HY, ed. Psychopharmacology. The third generation of progress. New York: Raven Press, 1987:1041–9.Google Scholar
  65. 65.
    Macher JP, Sichel JP, Serre C, Von Frenckell R, Huck JC, Demarez JP. Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders. Neuropsychobiology 1989;22:77–82.PubMedGoogle Scholar
  66. 66.
    Von Frenckell R, Ansseau M, Serre C, Sutet P. Pooling two controlled comparisons of milnacipran (F2207) and amitriptyline in endogenous inpatients. A new approach in dose ranging studies. Int Clin Psychopharmacol 1990;5:49–56.PubMedGoogle Scholar
  67. 67.
    Ansseau M, Von Frenckell R, Mertens C, et al. Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive inpatients. Psychopharmacology 1989;98:163–8.PubMedGoogle Scholar
  68. 68.
    Krause W, Kuhne G, Matthes H. Pharmacokinetics of the antidepressant rolipram in healthy volunteers. Xenobiotica 1989;19:683–92.PubMedGoogle Scholar
  69. 69.
    Nutt D, Glue P. Monoamine oxidase inhibitors: rehabilitation from recent research? Br J Psychiatry 1989;154:287–91.PubMedGoogle Scholar
  70. 70.
    Nolen WA, Bouvy PF, Haffmans J. MAO-inhibitors in resistant depression. Biol Psychiatry 1991;29:58S.Google Scholar
  71. 71.
    Quitkin FM, McGrath PJ, Stewart JW, et al. Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression. Arch Gen Psychiatry 1989;46:787–93.PubMedGoogle Scholar
  72. 72.
    Delini-Stula A, Radeke E, Waldmeier PC. Basic and clinical aspects of the activity of the new monoamine oxidase inhibitors. Psychopharmacol Ser 1988;5: 147–58.PubMedGoogle Scholar
  73. 73.
    Amrein R, Allen SR, Guentert TW, et al. The pharmacology of reversible monomamine oxidase inhibitors. Br J Psychiatry 1989;155 Suppl 6:66–71.Google Scholar
  74. 74.
    Laux G. Moclobemid in der Depressionsbehandlung — eine Übersicht. Psychiatr Prax 1989;16 Suppl 1:37–40.PubMedGoogle Scholar
  75. 75.
    Stabl M, Bizière K, Schmid-Burgk W, Amrein R. Review of comparative clinical trials. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states. J Neural Transm Suppl 1989;28:77–89.PubMedGoogle Scholar
  76. 76.
    Möller HJ, Wendt G. Brofaromin — ein selectiver, reversibler und kurzwirksamer MAO-A-Hemmer. Psychiatr Prax 1989;16 Suppl 1:32–6.PubMedGoogle Scholar
  77. 77.
    Huybrechts I. The pharmacology of alprazolam: a review. Clin Ther 1991;13:100–17.PubMedGoogle Scholar
  78. 78.
    Feighner JP. A review of controlled studies of adinazolam mesylate in patients with major depressive disorder. Psychopharmacol Bull 1986;22:186–91.PubMedGoogle Scholar
  79. 79.
    Warner MD, Peabody CA, Whiteford HA, Hollister LE. Alprazolam as an antidepressant. J Clin Psychiatry 1988;49:148–50.PubMedGoogle Scholar
  80. 80.
    Sheehan DV. The treatment of panic and phobic disorders. In: Bernstein JG, ed. Clinical Psychopharmacology. 2nd ed. Boston: John Wright, 1984;93–109.Google Scholar
  81. 81.
    Ballenger JC, Burrows GD, DuPont RL Jr, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry 1988;45:413–22.PubMedGoogle Scholar
  82. 82.
    Dunner DL, Ishiki D, Avery DH, Wilson LG, Hyde TS. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. J Clin Psychiatry 1986:47;458–60.PubMedGoogle Scholar
  83. 83.
    Tesar GE, Rosenbaum JF, Pollack MH et al. Doubleblind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991;52:69–76.PubMedGoogle Scholar
  84. 84.
    Charney DS, Woods SW. Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J Clin Psychiatry 1989:50;418–23.PubMedGoogle Scholar
  85. 85.
    Goa KL, Heel RC. Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 1986;32:48–65.PubMedGoogle Scholar
  86. 86.
    Gerlach J, Christensen JK, Christensen TL, Elley J, Jensen JP, Larsen SB. Suriclone and diazepam in the treatment of neurotic anxiety. A double-blind crossover trial. Psychopharmacology 1987;93:296–300.PubMedGoogle Scholar
  87. 87.
    Morselli PL. On the therapeutic action of alpidem in anxiety disorders: an overview of the European data. Pharmacopsychiatry 1990;23 Suppl 3:129–34.PubMedGoogle Scholar
  88. 88.
    Wheatley D. New hypnotic agents: clinical studies in general practice. Pharmacol Biochem Behav 1988;29:811–3.PubMedGoogle Scholar
  89. 89.
    Langendijk PNJ, Van Loenen AC, Jonker C. Farmacotherapie bij Alzheimer-type dementie [Pharmaco-therapy in Alzheimer-type dementia]. Pharm Weekbl 1988;123:1161–70.Google Scholar
  90. 90.
    Chatellier G, Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Francais d'Etude de la Tetrahydroaminoacridine. BMJ 1990;300:495–9.PubMedGoogle Scholar
  91. 91.
    Gauthier S, Bouchard R, Lamontagne A, et al. Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. Results of a Canadian double-blind, crossover, multicenter study. N Engl J Med 1990;322:1272–6.PubMedGoogle Scholar
  92. 92.
    Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry 1990;157:894–901.PubMedGoogle Scholar
  93. 93.
    Sheehan DV, Zak JP, Miller JA Jr, Fanous BS. Panic disorder: the potential role of serotonin reuptake inhibitors. J Clin Psychiatry 1988;49 Suppl:30–6.PubMedGoogle Scholar
  94. 94.
    Liebowitz MR. Antidepressants in panic disorders. Br J Psychiatry 1989;155 Suppl 6:46–52.Google Scholar
  95. 95.
    Liebowitz MR, Hollander E, Schneier F, et al. Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatr Scand 1990;82 Suppl 360:29–34.Google Scholar
  96. 96.
    Murphy DL, Pato MT, Pigott TA. Obsessivecompulsive disorder: treatment with serotonin-selective uptake inhibitors, azapirones, and other agents. J Clin Psychopharmacol 1990;10 Suppl 3:91S–100S.PubMedGoogle Scholar
  97. 97.
    McTavish D, Benfield P. Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs 1990;39:136–53.PubMedGoogle Scholar
  98. 98.
    Pope HG Jr, Hudson JI. Antidepressant drug therapy for bulimia: current status. J Clin Psychiatry 1986: 47:339–45.PubMedGoogle Scholar
  99. 99.
    Frost RE, Messiha FS. Clinical uses of lithium salts. Brain Res Bull 1983;11:219–31.PubMedGoogle Scholar
  100. 100.
    Murray JB. New applications of lithium therapy. J Psychol 1990;124:55–73.PubMedGoogle Scholar
  101. 101.
    Jefferson JW. Lithium: the present and the future. J Clin Psychiatry 1990;51 Suppl:4–8.Google Scholar
  102. 102.
    Ballenger JC. The use of anticonvulsants in manicdepressive illness. J Clin Psychiatry 1988;49 Suppl:21–5.Google Scholar
  103. 103.
    Post RM. Non-lithium treatment for bipolar disorder. J Clin Psychiatry 1990;51 Suppl:9–19.Google Scholar
  104. 104.
    Greendyke RM, Kanter DR, Schuster DB, Verstreate S, Wootton J. Propranolol treatment of assaultive patients with organic brain disease. A double-blind crossover, placebo-controlled study. J Nerv Ment Dis 1986;174:290–4.PubMedGoogle Scholar
  105. 105.
    Ananth J, Lin KM. Propranolol in psychiatry. Therapeutic uses and side effects. Neuropsychobiology 1986;15:20–7.PubMedGoogle Scholar
  106. 106.
    Berlant JL. One more look at propranolol for the treatment of refractory schizophrenia. Schizophr Bull 1987;13:705–14.PubMedGoogle Scholar
  107. 107.
    Luchins DJ, Dojka D. Lithium and propranolol in aggression and self-injurious behavior in the mentally retarded. Psychopharmacol Bull 1989;25:372–5.PubMedGoogle Scholar
  108. 108.
    Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 1990;10:12–21.PubMedGoogle Scholar
  109. 109.
    Bond WS. Psychiatric indications for clonidine: the neuropharmacologic and clinical basis. J Clin Psychopharmacol 1986;6:81–7.PubMedGoogle Scholar
  110. 110.
    Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend 1988;21:253–9.PubMedGoogle Scholar
  111. 111.
    Dose M, Emrich HM, Cording-Tommel C, Von Zerssen D. Use of calcium antagonists in mania. Psychoneuroendocrinology 1986;11:241–3.PubMedGoogle Scholar
  112. 112.
    Price WA. Antipsychotic effects of verapamil in schizophrenia. Hillside J Clin Psychiatry 1987;9:225–30.PubMedGoogle Scholar
  113. 113.
    Duncan E, Adler L, Angrist B, Rotrosen J. Nifedipine in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1990;10:414–6.PubMedGoogle Scholar
  114. 114.
    Roccaforte WH, Burke WJ. Use of psychostimulants for the elderly. Hosp Commun Psychiatry 1990;41:1330–3.Google Scholar
  115. 115.
    Satel SL, Nelson JC. Stimulants in the treatment of depression: a critical overview. J Clin Psychiatry 1989;50:241–9.PubMedGoogle Scholar
  116. 116.
    Walters A, Hening W, Chokroverty S, Fahn S. Opioid responsiveness in patients with neuroleptic-induced akathisia. Mov Disord 1986;1:119–27.PubMedGoogle Scholar
  117. 117.
    Loonen AJM, Verwey HA, Roels PR, Van Bavel LP, Doorschot CH. Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients? A negative, double-blind, placebocontrolled trial. J Clin Psychopharmacol 1992;12:39–42.PubMedGoogle Scholar
  118. 118.
    Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990;47:577–85.PubMedGoogle Scholar
  119. 119.
    Den Boer JA, Westenberg HG. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988;3: 59–74.Google Scholar
  120. 120.
    Eison AS, Temple DL. Buspirone. Review of its pharmacology and current perspectives on its mechanism of action. Am J Med 1986;80:1–9.Google Scholar
  121. 121.
    Goa KL, Ward A. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986;32:114–29.PubMedGoogle Scholar
  122. 122.
    Eison AS. Azapirones: history of development. J Clin Psychopharmacol 1990:10 Suppl 3:2S–5S.PubMedGoogle Scholar
  123. 123.
    Eison MS. Serotonin: a common neurobiologic substrate in anxiety and depression. J Clin Psychopharmacol 1990;10 Suppl 3:26S-30S.PubMedGoogle Scholar
  124. 124.
    Schipper J, Tulp MT, Sijbesma H. Neurochemical profile of eltoprazine. Drug Metab Drug Interact 1990;8:85–114.Google Scholar
  125. 125.
    Peroutka SJ. 5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization. Trends Neurosci 1988;11:496–500.PubMedGoogle Scholar
  126. 126.
    Schoeffter P, Hoyer D. How selective is GR 43175? Interactions with functional 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol 1989;340:135–8.PubMedGoogle Scholar
  127. 127.
    Leysen JE. Use of 5-HT receptor agonists and antagonists for the characterization of their respective receptor sites. In: Boulton AB, Baker GB, Juorio AV, eds. Drugs as tools in neurotransmitter research. Clifton:Humana Press, 1989:299–348.Google Scholar
  128. 128.
    Parsons AA. 5-HT receptors in human and animal cerebrovasculature. TiPS 1991;12:310–5.PubMedGoogle Scholar
  129. 129.
    McKenna DJ, Peroutka SJ. Differentiation of 5-hydroxytryptamine2 receptor subtypes using (125I)-R-(−)2,5-dimethoxy-4-iodo-phenylisopropylamine and (3H)-ketanserin. J Neurosci 1989;9:3482–90.PubMedGoogle Scholar
  130. 130.
    Branchek T, Adham N, Macchi M, Kao HT, Hartig PR. (3H)-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and (3H)ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor. Mol Pharmacol 1990;38:604–9.PubMedGoogle Scholar
  131. 131.
    Ceulemans DL, Hoppenbrouwers ML, Gelders YG, Reyntjens AJ. The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry 1985;18:303–5.PubMedGoogle Scholar
  132. 132.
    Bressa GM, Marini S, Gregori S. Serotonin S2 receptors blockage and generalized anxiety disorders. A double-blind study on ritanserin and lorazepam. Int J Clin Pharmacol Res 1987;7:111–9.PubMedGoogle Scholar
  133. 133.
    Bersani G, Pozzi F, Marini S, Grispini A, Pasini A, Ciani N. 5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. Acta Psychiatr Scand 1991;83:244–8.PubMedGoogle Scholar
  134. 134.
    Duinkerke SJ, Botter PA, Van Haaften AJ, Boom AJ, Van Laarhoven JHM, Busard HLSM. Ritanserin in the treatment of negative symptoms in schizophrenic patients. Biol Psychiatry 1991;29:654S.Google Scholar
  135. 135.
    Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 1990;13:500–6.PubMedGoogle Scholar
  136. 136.
    Anonymous. Ondansetron: Facts and comparisons. Hosp Pharm 1991;26:252–253.Google Scholar
  137. 137.
    Izquierdo I, Medina JH. GABA-A receptor modulation of memory: the role of endogenous benzodiazepines. TiPS 1991;12:260–5.PubMedGoogle Scholar
  138. 138.
    Olivier B, Mos J, Rasmussen D. Behavioural pharmacology of the serenic eltoprazine. Drug Metab Drug Interact 1990;8:31–83.Google Scholar
  139. 139.
    Goldsmith MF. Drug review, approval process changing. JAMA 1985;254:2221,2227.PubMedGoogle Scholar
  140. 140.
    Sheck L, Cox C, Davis HT, Trimble AG, Wardell WM, Hansen R. Success rates in the United States drug development system. Clin Pharmacol Ther 1984;36:574–83.PubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1992

Authors and Affiliations

  • Anton J. M. Loonen
    • 1
  1. 1.Central Hospital Pharmacy 1ME 's-Hertogenboschthe Netherlands

Personalised recommendations